fda tirzepatide obesity approval for Zepbound (tirzepatide) injection, the first and only treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Tirzepatide for Medical Weight Loss

The majority of visits involved digestive issuessuch as nausea, vomiting, and diarrheamost often linked to incorrect dosing

Source:The Lancet Background What retatrutide is Retatrutide, also known by its development code LY3437943, is an investigational once-weekly injectable being developed by Eli Lilly and Company

Early signs of mild to moderate dehydration include: Increased thirst Dry mouth, lips, or tongue Decreased urine output or dark yellow urine Fatigue or unusual tiredness Headache Dizziness or lightheadedness, especially upon standing Dry skin with decreased elasticity Constipation or worsening of existing constipation A practical self-assessment tool is urine color monitoring

Extensive research continues to underscore the efficacy of semaglutide injections in facilitating weight loss, emphasizing the shift towards treating obesity as a chronic metabolic condition rather than solely relying on lifestyle modifications